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ABSTRACT
Introduction: Acute kidney injury (AKI) occurs in
55–60% of critically ill patients, and sepsis is the most
common underlying cause. No pharmacological
treatment options are licensed to treat sepsis-
associated AKI (SA-AKI); only supportive renal
replacement therapy (RRT) is available. One of the
limited number of candidate compounds in clinical
development to treat SA-AKI is alkaline phosphatase
(AP). The renal protective effect of purified bovine
intestinal AP has been demonstrated in critically ill
sepsis patients. To build on these observations, a
human recombinant AP (recAP) was developed, of
which safety and efficacy in patients with SA-AKI will
be investigated in this trial.
Methods: This is a randomised, double-blind,
placebo-controlled, 4-arm, proof-of-concept, dose-
finding adaptive phase IIa/IIb study, conducted in
critically ill patients with SA-AKI. A minimum of 290
patients will be enrolled at ∼50 sites in the European
Union and North America. The study involves 2 parts.
Patients enrolled during Part 1 will be randomly
assigned to receive either placebo (n=30) or 1 of 3
different doses of recAP (n=30 per group) once daily
for 3 days (0.4, 0.8 or 1.6 mg/kg). In Part 2, patients
will be randomly assigned to receive the most
efficacious dose of recAP (n=85), selected during an
interim analysis, or placebo (n=85). Treatment must be
administered within 24 hours after SA-AKI is first
diagnosed and within 96 hours from first diagnosis of
sepsis. The primary end point is the area under the
time-corrected endogenous creatinine clearance curve
from days 1 to 7. The key secondary end point is RRT
incidence during days 1–28.
Ethics and dissemination: This study is approved
by the relevant institutional review boards/independent
ethics committees and is conducted in accordance
with the ethical principles of the Declaration of
Helsinki, guidelines of Good Clinical Practice, Code of
Federal Regulations and all other applicable
regulations. Results of this study will reveal the efficacy
of recAP for the improvement of renal function in
critically ill patients with SA-AKI and will be published
in a peer-reviewed scientific journal.
Trial registration number: NCT02182440;
Pre-results.
Strengths and limitations of this study
▪ This is the first randomised controlled trial in
sepsis-associated acute kidney injury (SA-AKI)
with well-controlled comparable standard of
care, as participating institutions are required to
adhere to the Surviving Sepsis Campaign and
KDIGO Clinical Practice Guideline for AKI recom-
mendations and to strictly defined renal replace-
ment therapy starting and stopping criteria.
▪ The study was designed by a group of leading
global experts in AKI and sepsis, with input from
the US Food and Drug Administration, the
European Medicines Agency and several local
European country authorities, resulting in a
dose-finding adaptive trial.
▪ Results of this trial will allow us to draw conclu-
sions on the efficacy of human recombinant
alkaline phosphatase in the improvement of renal
function and related clinical parameters.
▪ Regardless of the outcome of the intervention,
data from the placebo group will provide valuable
information on clinical outcome in patients with
SA-AKI.
▪ Strict inclusion criteria and time-windows may
limit generalisation of the results to the entire
population of critically ill patients with SA-AKI.
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INTRODUCTION
Acute kidney injury (AKI) is common in critically ill
patients and associated with signiﬁcant morbidity and
mortality. The intensive care unit (ICU) incidence of
AKI is 55–60% with an associated mortality of more than
27%.1 Patients surviving an AKI episode have an
increased risk to develop chronic kidney failure, result-
ing in a tremendous burden for the patient and society.2
AKI may occur after cardiovascular surgery, administra-
tion of nephrotoxic drugs, trauma, burns and sepsis,
with the latter being the most frequent cause of AKI.3
Sepsis presents with clinical manifestations of systemic
inﬂammation combined with suspicion or evidence of
an infection and is a major cause of multiple organ dys-
function and death in the ICU.4 The pathogenesis of
sepsis-associated AKI (SA-AKI) is believed to be an inter-
play of systemic and renal inﬂammation, hypoxia and
dysregulated renal bioenergetics.5 There are no pharma-
cological interventions approved for the treatment of
SA-AKI. Currently, the only supportive treatment option
available is renal replacement therapy (RRT).
A potent new candidate drug in clinical development
to treat or prevent SA-AKI is alkaline phosphatase (AP).
AP is a dephosphorylating, membrane-bound, endogen-
ously occurring enzyme, exerting detoxifying effects
through dephosphorylation of endotoxins, involved in
sepsis pathogenesis6 7 and other proinﬂammatory com-
pounds, including extracellular ATP.8 Several isoenzymes
exist, namely intestinal, placental, germ-cell and tissue
non-speciﬁc (liver/kidney/bone) AP, illustrating the
broad expression throughout the body.9
Previously, clinical trials in healthy volunteers and
patients with sepsis, with or without AKI, have estab-
lished the tolerability and potential efﬁcacy of puriﬁed
bovine intestinal AP (biAP).10–12 In patients with
SA-AKI, biAP signiﬁcantly improved renal function
according to the combined end point of endogenous
creatinine clearance, requirement for RRT and duration
of RRT. Moreover, a range of markers of systemic inﬂam-
mation, renal function and renal damage in blood and
urine demonstrated improvement, suggesting that a sys-
temic anti-inﬂammatory effect induced by biAP pre-
vented further renal injury. Following these encouraging
results, a human recombinant AP (recAP) has been
developed as a pharmaceutically acceptable replacement
for bovine-derived AP. In order to improve enzyme sta-
bility, while maintaining catalytic function, the crown
domain of a human intestinal AP is replaced with the
crown domain of human placental AP.13 In line with pre-
clinical and clinical studies using puriﬁed biAP, animal
studies with recAP revealed potent anti-inﬂammatory
activity preserving function14 and histological integrity of
the affected kidneys (unpublished data) and administra-
tion to healthy volunteers did not raise any safety
concerns.15 Therefore, therapeutic application of
recAP is predicted to exert potent tissue protective and
anti-inﬂammatory effects in patients with SA-AKI. In
order to investigate this hypothesis, a randomised
placebo-controlled phase II trial is being conducted with
recAP in critically ill patients suffering from SA-AKI.
METHODS AND ANALYSIS
Design and setting
A randomised, double-blind, placebo-controlled, four-
arm, parallel-group, proof-of-concept, dose-ﬁnding adap-
tive phase IIa/IIb study is being conducted in critically
ill patients with SA-AKI. It is expected that the patients
will be recruited by ∼50 sites across the European Union
and North America. Participating institutions will be
required to adhere to the Surviving Sepsis Campaign
201216 and 2012 KDIGO (Kidney Disease: Improving
Global Outcomes) Clinical Practice Guideline for AKI
recommendations.17 The study involves two parts with
an interim analysis between the parts (ﬁgure 1), with
continued recruitment during this interim analysis.
Patients enrolled during Part 1 and during the interim
analysis will be randomly assigned to receive either
placebo or one of three different doses of recAP once
daily for 3 days. The interim analysis on safety and the
primary end point will be performed after the 120th
patient of Part 1 has completed the day 7 visit of the
study to select the dose to be administered in Part
2. The dose chosen will be the most efﬁcacious dose of
recAP on the primary end point in Part 1, provided
there are no safety issues with that dose as judged by the
data monitoring committee (DMC). In Part 2, patients
will be randomly assigned to receive either placebo or
the dose of recAP selected during the interim analysis.
Patients recruited during the interim analysis period to
the dose selected in Part 2 will form part of the Part 2
population, but those recruited to the doses that are not
selected will be included in the Part 1 population. The
duration of the study is deﬁned for each patient as the
date signed written informed consent is provided
through the last follow-up visit on day 90 (ﬁgure 2).
This study is reported in accordance with the Standard
Protocol Items: Recommendations for Interventional
Trial (SPIRIT) guidelines.18
Study objectives
Primary objectives
The primary objectives are to investigate the optimal
therapeutic dose and effect of recAP on renal function
and related clinical parameters in patients with SA-AKI.
Secondary objectives
The secondary objectives are to investigate the safety
and tolerability, pharmacokinetics (in the ﬁrst 120
patients from Part 1 only), immunogenic potential and
the effect on quality of life of recAP in patients with
SA-AKI.
Other objectives
The other objectives are to determine whether speciﬁc
patient groups beneﬁt most from recAP treatment and
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whether patient groups that are non-responders can be
identiﬁed. The identiﬁcation of such groups will be
based on several baseline characteristics, including
kidney function markers and biomarkers for tubular
injury and systemic inﬂammation.
Patient selection
A minimum of 290 patients will be enrolled, at least 120
patients in Part 1 and at least 170 patients in Part
2. Potential patients who have been admitted to the ICU
will undergo a prescreening and, once informed
consent is obtained, will undergo screening assessments
to determine their eligibility. As soon as possible when
all of the inclusion criteria and none of the exclusion
criteria are met (box 1), and after conﬁrmation of con-
tinuing AKI by either a ﬂuid-corrected serum creatinine
assessment or persistence of attenuated urine output,
patients will be randomly assigned to a treatment group,
undergo baseline determinations and start treatment
with study drug (day 1). Treatment must be adminis-
tered within 24 hours, at the latest, after SA-AKI is ﬁrst
diagnosed and within 96 hours from fulﬁlling sepsis cri-
teria. Coincident with the interim analysis, but inde-
pendent from it, some eligibility criteria (eg, age,
weight, time-window of sepsis diagnosis, time-window of
AKI diagnosis) were slightly modiﬁed to facilitate patient
inclusion in the second part of the trial (see online
supplementary table S1). These adjustments were con-
sidered to be unlikely to materially inﬂuence the
characteristics of the subject population or to impact the
potential risk–beneﬁt of recAP. In addition, to achieve
adequate participant enrolment, best practices will be
shared via national coordinator meetings and if neces-
sary, additional sites will be recruited and dormant sites
will be closed.
Randomisation
Patients will be randomly assigned to receive either placebo
or one of three doses of recAP using a 1:1:1:1 allocation
ratio. The randomisation schedule will be stratiﬁed by site.
An independent statistician will generate a permuted block
randomisation schedule for an interactive voice/web
Figure 1 Trial flow. ICF, informed consent form; recAP, human recombinant alkaline phosphatase; RRT, renal replacement
therapy; SA-AKI, sepsis-associated acute kidney injury; h, hours.
Figure 2 Timeline. IV, intravenous; SA-AKI, sepsis-associated acute kidney injury; h, hours.
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Box 1 Patient entry selection
Inclusion criteria
▸ Has informed consent form signed by patient or legal representatives or independent investigator, according to local rules and
regulations
▸ Is aged 18–85 years, inclusive
▸ Is admitted to the intensive care unit or intermediate care unit
▸ Has diagnosis of sepsis (<96 hours prior to first study drug administration or <72-hour prior to acute kidney injury (AKI) diagnosis),
according to criteria defined by the American College of Chest Physicians/Society of Critical Care Medicine,19 based on:
A. A proven or strongly suspected bacterial infection
B. At least two of the following four SIRS criteria within a timeframe of 72 hours at the time of AKI diagnosis. Note: it is not required that
symptoms are present simultaneously at study randomisation:
1. Core temperature >38°C or <36°C
2. Heart rate >90 bpm (unless the patient has a medical condition known to increase heart rate or is receiving treatment to prevent
tachycardia
3. Respiratory rate >20 breaths/min, PaCO2 <32 mm Hg or the use of mechanical ventilation for an acute respiratory process
4. White cell count >12 000/mm3 or <4000/mm3 or a differential count showing >10% immature neutrophils
▸ Has first diagnosis of AKI, defined as AKI Stage 1 or greater, according to the following AKIN criteria (Note: adjusted in regard to
time-window):
A. Urinary output <0.5 mL/kg/h for >6 hours following adequate fluid resuscitation when applicable, in the absence of underlying primary
renal disease, or
B. Increase (absolute) in serum creatinine >26.2 µmol/L (0.30 mg/dL) compared with a serum creatinine value within the previous
48 hours, or presumed to have occurred in the previous 48 hours when compared with a reference creatinine value (see below), or
C. Increase (relative) in serum creatinine to >150% (>1.5-fold) compared with a serum creatinine value in the previous 48 hours or pre-
sumed to have occurred in the previous 48 hours, when compared with a reference creatinine value (in the absence of primary under-
lying renal disease).
D. The reference creatinine value is a serum creatinine value in the following order of preference:
1. Lowest value within 3 months of the hospital admission. If not available:
2. At hospital admission. If not available:
3. At ICU admission. If not available:
4. Lowest value between 3 and 12 months prior to hospital admission
▸ When the diagnosis of AKI is made according to one of the AKIN serum creatinine criteria, continuing AKI needs to be confirmed by a
confirmative fluid-corrected serum creatinine measure, defined as no decrease in serum creatinine ≥26.2 µmol/L (≥0.30 mg/dL). The
result must be available prior to randomisation. Administration of study treatment must be started within 24 hours after first AKI
diagnosis
▸ When the AKI diagnosis was made according to the AKIN urine output criteria, the oliguria or anuria should still meet the AKIN urine
output criteria prior to randomisation. Administration of study treatment must be started within 24 hours after first AKI diagnosis
Exclusion criteria
▸ Woman of childbearing potential with a positive pregnancy test (blood or urine), pregnant or breast feeding
▸ Weighs more than 115 kg (253 lb)
▸ Has life support limitations (eg, do not intubate, do not dialyse, do not resuscitate)
▸ Is known to be HIV-positive
▸ Has urosepsis*
▸ Is already on renal replacement therapy (RRT) or a decision has been made to initiate RRT within 24 hours after planned start of study
drug administration
▸ Is receiving immunosuppressant treatment or is on chronic high doses (high-dose therapy exceeding 2 weeks of treatment) of steroids
equivalent to prednisone/prednisolone 0.5 mg/kg/day, including solid organ transplant patients. Patients with septic shock treated with
hydrocortisone (eg, 3×100 mg) can be included
▸ Is expected to have rapidly fatal outcome (within 24 hours)
▸ Has known, confirmed fungal sepsis
▸ Has advanced chronic liver disease, confirmed by a Child-Pugh score of 10–15 (Class C)
▸ Has acute pancreatitis with no established source of infection
▸ Has participated in another investigational study within 30 days prior to enrolment into the study
▸ Is not expected to survive for 28 days due to medical conditions other than SA-AKI, including cancer (previous haematological malignan-
cies that are not actively treated allowable), end-stage cardiac disease, cardiac arrest requiring cardiopulmonary resuscitation or with
pulseless electrical activity or asystole within the past 30 days, end-stage lung disease and end-stage liver disease
▸ Has known prior history of CKD with a documented eGFR <60 mL/min by a commonly used formula such as MDRD or CKD-EPI, known
GFR <60 mL/min or a known history of persistent creatinine level ≥150 μmol/L (1.70 mg/dL) prior to entry for reasons other than the
current sepsis condition†
▸ Has diagnosis of malaria or other parasite infections
▸ Has burns on >20% of body surface
▸ Has had AKI diagnosis according to the AKI inclusion criteria for a period longer than 24 hours prior to study drug administration
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response system (IVRS/IWRS), which will link sequential
patient randomisation numbers to treatment codes. After
informed consent has been obtained, the IVRS/IWRS pro-
vides a patient number at screening and retains a unique
randomisation number for all patients. Once the screening
assessments are performed, data have been reviewed by an
investigator and the patient is considered to be eligible, the
investigator will contact the IVRS/IWRS to randomly assign
the patient a treatment number through IVRS/IWRS.
Once it has been decided which is the most efﬁcacious
dose of recAP on the primary end point to be administered
in Part 2, the codes for the treatment groups corresponding
to the two dropped doses will be discontinued, and 1:1
treatment allocation will continue using the codes for the
remaining treatments (1 active, 1 placebo).
Informed consent
Informed consent (see online supplementary appendix
I) will be obtained before any study-speciﬁc procedures
are performed. Country-speciﬁc regulations regarding
the use and collection of personal data and biological
specimens, ancillary care, and ﬁnancial care to those
who suffer from harm will be followed at each site. It is
anticipated by the very nature of the study that many
patients who will be eligible for this protocol due to
their severe underlying condition will not be able to
provide informed consent themselves for various
reasons. In a situation where a patient is unable to
provide consent, the patient’s legally authorised repre-
sentative may provide written consent as approved by the
institutional-speciﬁc guidelines. Informed consent may
be obtained from an independent consulting physician
in countries where regulation and institution guidelines
permit. This form of consent can only be used when the
patient and legally authorised representative are unable
to provide consent. In cases where the initial informed
consent is obtained from a legal representative or an
independent consulting physician, the patient also must
consent as soon as they are able. The investigator shall
retain the signed original Informed Consent Form (ICF)
and give a copy of the signed original form to the
patient or legal representative.
Blinding
All people involved in the study will be blinded to treat-
ment assignment. The randomisation schedule will be
held by an independent, non-blinded statistics team at a
different regional location and will not be revealed until
all patients have completed the study and the database has
been ﬁnalised for the end of the study. The non-blinded
interim analysis will be conducted and delivered to the
independent data monitoring committee by the non-
blinded biostatistics team, located at a different site to the
blinded team. A patient’s treatment assignment will not be
broken until the end of the study, unless knowledge of the
treatment assigned to the patient is necessary to guide
medical treatment of the patient. The determination of
AP activity in plasma, often part of the routine clinical
chemistry panel, could lead to non-blinding and to errone-
ous interpretation of liver function, as the recAP adminis-
tered will increase the AP activity, exceeding many times
the reference range AP levels. Therefore, AP activity levels
from samples taken during the ﬁrst 14 days of the study
are not allowed to be determined/reported to the study
teammembers or to any other study staff member involved
in the conduct of the study.
Study intervention
Patients randomly assigned to receive recAP in Part 1
will receive one of the following three doses of recAP:
0.4 mg/kg (250 U/kg), 0.8 mg/kg (500 U/kg) or
1.6 mg/kg (1000 U/kg). Study drug will be administered
by 1-hour intravenous infusion as soon as possible, but
within 24 hours after SA-AKI is ﬁrst diagnosed, on day 1,
and 24±1 hours later on days 2 and 3. A total volume of
50 mL will be infused at a constant rate of 50 mL/hour.
▸ Is anticipated to be treated with non-continuous RRT from day 1 to day 7
▸ During day 1 to day 7, continuous RRT is anticipated to be started or stopped not according to per protocol criteria
▸ The AKI is most likely attributable to other causes than sepsis, such as nephrotoxic drugs (NSAIDs, contrast, aminoglycosides) and renal
perfusion-related (acute abdominal aortic aneurysm, dissection, renal artery stenosis)
▸ Improvement in serum creatinine of at least 26.2 µmol/L (0.30 mg/dL) prior to administration of the study drug
▸ Patients who use nephrotoxic medication and who fulfil the SA-AKI inclusion criteria at screening are not eligible if the use of this
nephrotoxic medication is planned to continue (eg, NSAIDs, ACE inhibitors, gentamycin, tobramycin)
▸ Has a history of known intravenous drug abuse
▸ Is an employee or family member of the investigator or study site personnel
▸ Has active haematological malignancy
*As urogenital obstruction, frequently observed during urosepsis, may also account for an increase in serum creatinine levels, it is not
possible to define which proportion might be due to SA-AKI. Therefore, urosepsis patients are excluded.
†CKD is a disease with a distinct pathophysiology compared with AKI. Also, if eGFR is impaired, the chances of an intervention to
prevent further deterioration are limited. To increase homogeneity of the study population, these patients are therefore excluded.
AKI, acute kidney injury; AKIN, acute kidney injury network; CDK, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology
Collaboration; eGFR, estimated glomerular filtration rate; ICU, intensive care unit; IV, intravenous; MDRD, Modification of Diet in Renal
Disease; NSAIDs, non-steroidal anti-inflammatory drugs; RRT, renal replacement therapy; SIRS, systemic inflammatory response
syndrome.
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The preferred route for study drug administration is
through a central venous line; if this is not possible, a
peripheral line is acceptable. Study drug is being admi-
nistered separately from any concomitant drugs using a
dedicated lumen of the catheter. At the start of each
drug administration, the exact volume of recAP or
placebo to be administered to each patient will be calcu-
lated on the basis of the patient’s hospital admission
weight. Patients weighing between 95 and 115 kg will
receive the same dose as that for patients weighing
100 kg. The volume of the placebo and the volume of
the active doses of recAP are identical. RecAP is supplied
as a clear, colourless, pyrogen-free solution for intraven-
ous infusion with a content of 40 mg per phial at
8.0 mg/mL in an aqueous buffer. Matching placebo is
supplied in an identical manner as the same aqueous
buffer. RecAP and matching placebo will be prepared in
randomised treatment packs comprising three daily
doses and shipped to the clinical site. Each pack will
contain a (randomised) dosage for one patient and will
contain a sufﬁcient quantity for dispensing during the
3-day double-blind treatment period. The content of the
vials will be used to ﬁll an intravenous dosing syringe
and will be dose adjusted to an appropriate volume cor-
responding to the body weight of the patient, followed
by the addition of physiological saline solution to a total
of 50 mL. All study drug is to be stored in a lockable
storage facility under appropriate and monitored phar-
macy conditions.
Concomitant medications
After randomisation, the administration of nephrotoxic
drugs, such as contrast agents, non-steroidal anti-
inﬂammatory drugs, ACE inhibitors, angiotensin recep-
tor blockers, gentamycin or tobramycin should be
avoided where possible, as recommended in the KDIGO
Clinical Practice Guideline for AKI recommendations.17
Outcome measures
Primary end point
The primary end point is the area under the time-
corrected endogenous creatinine clearance curve from
day 1 (ﬁrst measurement after treatment) to day 7,
inclusive (AUC1–7), with the creatinine clearance curve
being the mean creatinine clearance on each day.
Time-corrected endogenous creatinine clearance is
assessed on each day during a 6±1 hour period with
serum creatinine measurements before and after the
urine collection period to calculate in mL/min as the
mean creatinine clearance over the period. Although
24-hour urine collection periods are the most accurate
to reliably determine creatinine clearance, a 6-hour
period is expected to be representative of the full
24 hours for that day.20 21 If there is no diuresis, the
clearance will be reported as 0 mL/min.
AUC1–7 is calculated as the average of the time-
corrected endogenous creatinine clearance values over
the 7 days. Speciﬁcally, denoting Ci as the mean time-
corrected endogenous creatinine clearance on day i,
AUC1–7 is deﬁned as:
AUC17 ¼ 17
P7
i¼1 Ci Any missing Ci values will be
handled by linear interpolation where possible, other-
wise they will be imputed by last observation carried
forward. When there are no preceding postbaseline
measurements to use, the baseline measurement from
day 0 (prior to treatment) will be carried forward.
Key secondary end point
The key secondary end point is RRT incidence during
the period day 1 (after ﬁrst treatment) to day 28, inclu-
sive. Should a patient die or withdraw from the study
during this period without recording RRT incidence, he
or she will be counted as having not required RRT.
From day 1 to day 7, only continuous modalities of RRT
are allowed. From day 8 onward, intermittent/non-
continuous modalities such as intermittent haemodialy-
sis are allowed. Criteria for the initiation and timing of
stopping of RRT are described in box 2. Although these
criteria are strongly preferred within the protocol
setting, based on clinical judgement, investigators may
deviate from these criteria.
Other secondary end points
Other secondary renal end points include the duration
of RRT over 28 days and renal function at day 28 (cre-
atinine clearance if available, or estimated GFR (eGFR)
Box 2 Start and stop criteria RRT
Initiation of RRT22*
▸ Anuria (negligible urine output for 6 hours)
▸ Severe oligura (urine output <200 mL over 12 hours)
▸ Hyperkalaemia (potassium concentrations >6.5 mmol/L)
▸ Severe metabolic acidosis (pH <7.2 despite normal or low
partial pressure of carbon dioxide in arterial blood)
▸ Volume overload (especially pulmonary oedema unresponsive
to diuretics)
▸ Pronounced azotaemia (urea concentrations >30 mml/L or
creatinine concentrations >300 μmol/L)
▸ Clinical complications of uraemia (eg, encephalopathy, pericar-
ditis, neuropathy)
Timing of stopping RRT23
▸ If (on continuous RRT or between intermittent haemodialysis
sessions) diuresis >30 mL/hour and there are no other indica-
tions for RRT, then endogenous creatinine clearance should
be calculated using a 6-hour urine collection period:
A. If endogenous creatinine clearance ≥20 mL/min, RRT
should be discontinued
B. If endogenous creatinine clearance ≤12 mL/min, RRT
should be continued
C. If endogenous creatinine clearance >12 and <20 mL/min,
continuation or termination will be the decision of the
treating physician
*Meeting one criterion makes the patient eligible for initiation of
RRT.
RRT, renal replacement therapy.
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according to the chronic kidney disease epidemiology
collaboration (CKD-EPI) formula) and at days 60 and
90 (eGFR). Clinical end points include liver enzymes
(aspartate aminotransferase, alanine aminotransferase,
γ-glutamyl transpeptidase, lactate dehydrogenase, biliru-
bin), lung function (PaO2/FiO2 ratio, positive
end-expiratory pressure and tidal volume), mechanical
ventilation over 28 days, shock over 28 days, SOFA scores
and mortality over 90 days. Biomarker end points
include kidney function markers (urine and serum cre-
atinine, blood urea nitrogen, sodium, proteinuria, frac-
tional excretion of sodium and urea and urine volume),
biomarkers for tubular injury (kidney injury molecule-1,
interleukin (IL)-18 and α-glutathione s-transferase) and
systemic inﬂammation (IL-6, C reactive protein and lipo-
polysaccharide (LPS)-binding protein), and recAP phar-
macokinetic properties.
Additional end points include composite end points
(combinations of need for RRT, mortality, eGFR and
hospitalisation for new AKI episode), serology, assessed
by IgG, IgE and total immunoglobulin, quality of life,
assessed by the EuroQol-5D questionnaire and ICU and
hospital length of stay over 90 days. The safety analyses
include (serious) adverse events (SAEs), laboratory
assessments (eg, antidrug antibodies), haematology, vital
signs and electrocardiography data.
Statistical and analytical plan
Sample size calculations
A sample size of n1=30 patients per treatment group in
Part 1 with an additional n2=85 patients recruited to the
optimal recAP dose and placebo treatment groups in
Part 2 (for a total sample size of n=290 patients) is
planned. Custom-programmed simulations were per-
formed using SAS software V.9.2 to determine power
and type I error rate of the chosen sample size and
design under a number of different dose–response scen-
arios. Each scenario assumed an SD of 49 mL/min for
the primary end point with an assumed response of
60 mL/min for the placebo group, and between 60 mL/
min (no treatment effect) and 79 mL/min (strong treat-
ment effect) for the recAP dose groups.
Fifty thousand simulations were performed to show
that the one-sided type I error rate is 2.4% (and hence
is well controlled at the one-sided 2.5% signiﬁcance
level). The power was deﬁned as the probability of
rejecting the null hypothesis (of no difference between
treatment groups) when one or more recAP dose
groups have an effective treatment effect, deﬁned as a
response of 69.5 mL/min. This was investigated across 7
scenarios with 10 000 simulations performed for each.
The chosen design achieved power of between 79% and
86% for scenarios with strong treatment effects for the
medium and high recAP dose groups and a varying
response for the low-dose group, and between 66% and
67% when only the high-dose group had a strong treat-
ment effect.
As the sample size determination is based on the
number of patients required for the intention-to-treat
(ITT) analysis, patients who are randomly assigned and
subsequently withdraw prior to completion of the study
will not be replaced.
Interim analysis
A non-blinded interim analysis will be conducted on the
Part 1 data to determine the optimal recAP dose for
Part 2. This analysis will compare the three recAP doses
and placebo from Part 1 on the primary efﬁcacy end
point and the safety data. The optimal dose is deﬁned as
the dose with the best safe improvement on creatinine
clearance compared with placebo. Unless the DMC have
safety concerns pertaining to speciﬁc dose level(s) of
recAP and/or the dose–response modelling of the
primary end point (Emax model) highlights unusual
trend(s), the optimal dose will be, preferably, the
highest dose of recAP. If there are safety concerns and/
or concerns with regard to the dose–response curve, the
optimal dose level will be selected among the dose levels
where there are no safety or/and dose–response model-
ling concerns. In that case, the effectiveness of a dose
level will be determined based on the one-sided
unadjusted p value for comparison with placebo on the
primary end point, that is, the dose with the smallest
p value will be considered the most effective dose.
Should more than one dose appear to be the most
effective with the same effect, the safety data as well as
the dose–response modelling should be closely exam-
ined for selecting the optimal dose.
Safety data being analysed include the use of concomi-
tant medications, adverse events (AEs), treatment emer-
gent AEs (TEAEs) and SAEs, laboratory assessments and
vital signs.
The results will only be reviewed by an independent
non-blinded DMC, who will make the dose selection
decision. The selected dose will be reported to the
sponsor in a blinded fashion. The study will not be pre-
maturely terminated in case a statistically signiﬁcant
beneﬁt is found during the interim analysis.
The study may be terminated for futility if none of the
three recAP doses in Part 1 show evidence of efﬁcacy for
the primary end point. Each recAP dose will only be
deemed futile if the one-sided, unadjusted p value for its
comparison with placebo is <0.8. If all of the doses in
Part 1 fulﬁl the futility criterion, then the DMC will rec-
ommend further discussion with the sponsor and
Steering Committee to determine whether the trial
should be terminated for futility.
Statistical analyses
Statistical analyses will be performed using SAS software
V.9.2 or later. Continuous variables will be summarised
using descriptive statistics, and categorical variables will
be summarised using frequency counts and percentages.
All statistical tests, primarily performed on the ITT set,
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will be two-sided and performed using a 5% signiﬁcance
level, leading to 95% (two-sided) CIs.
The analysis of the primary efﬁcacy end point will be
performed separately for Parts 1 and 2: for Part 1,
AUC1–7 will be compared between the three recAP
doses and placebo by an analysis of variance (ANOVA)
of the AUC1–7 with treatment and site as explanatory
variables, or corresponding non-parametric analyses if
appropriate. For Part 2, the optimal recAP dose will be
compared with placebo using the same ANOVA model
or corresponding non-parametric analyses if appropri-
ate. To address multiplicity, the type 1 error rate will be
controlled by combining the results for the primary efﬁ-
cacy end point from the interim analysis (Part 1) and
the ﬁnal analysis (Part 2), using the inverse normal
method.24
A hierarchical method will be employed to address
any multiplicity arising from the analysis of the key sec-
ondary end point, indicating that the optimal recAP
dose will be formally compared with placebo, using a
logistic regression model with treatment group and site
as explanatory variables, only if a statistically signiﬁcant
result is obtained from the combination test analysis of
the primary end point. Otherwise, the results will be
reported as exploratory analysis only.
All analyses performed on the other secondary end
points are for exploratory purposes only. Therefore, no
further multiplicity adjustment is required.
Data quality assurance
The sites will maintain source documentation and enter
patient data into the electronic case report form (eCRF)
as accurately as possible. eCRFs are accessed through
Medidata Rave (Medidata Solutions, New York,
New York, USA). This electronic data capture system is
validated and compliant with US Title 21 Code of
Federal Regulations (CFR) Part 11. Each person
involved with the study will have an individual user
name and password that allows for record traceability. A
quality review of the data will be performed by the site
with additional reviews by the clinical monitor through
100% source data veriﬁcation. Each eCRF is presented
as an electronic copy, allowing data entry by study site
staff, who can add and edit data, identify and resolve dis-
crepancies, and view records. This system provides
immediate direct data transfer to the database, as well as
immediate detection of discrepancies, enabling site
coordinators to resolve and manage discrepancies in a
timely manner. After all data reviews and query resolu-
tions are complete, the statistical analysis plan approved
and signed, and any summary/analysis populations
approved, the database will be locked.
Safety assessment
Medication errors
Since the study drug will be prepared, double-checked
and administered by trained hospital staff, and since the
dose levels under study have not caused any SAEs in
healthy volunteers,15 the risks for potential hazardous or
life-threatening events due to medication errors are con-
sidered to be minimal.
Overdose
In healthy volunteers, the maximum administered single
dose was 3.2 mg/kg (2000 U/kg) and this dose did not
result in any SAEs.15 As an example of a possible dose
error (eg, administration of the highest study dose for a
100 kg person to a 50 kg person), 1-day administration
of study drug still would not exceed the tested
maximum dose in healthy volunteers.
AEs report
All patients will be monitored closely for signs of adverse
reactions. AEs will be reported in the eCRF from the
time the patient signs the ICF until day 28 visit for all
AEs (including SAEs) regardless of its relationship to
study drug. Any AE that occurs during or after the ﬁrst
dose of study drug is considered treatment emergent.
The intensity of the AE will be rated as mild, moderate
or severe. In addition to patient observations, TEAEs will
be documented from any data collected on the AE page
of the eCRF (eg, laboratory values, physical examination
ﬁndings) or identiﬁed from review of other documents
(eg, patient diaries) that are relevant to patient safety.
When patients have left the hospital, they will be
instructed to contact the investigator at any time if any
symptoms develop. In the event of an SAE, the investiga-
tor may immediately stop treatment if it is considered in
the best interest of the patient. In case study drug is dis-
continued early, the patient will continue follow-up in
the study as per protocol. The assessment of the rela-
tionship of an AE to the administration of study drug
(unrelated, possible, probable, deﬁnite) is a clinical deci-
sion based on all available information at the time of
completion of the eCRF.
External data monitoring committee
An independent DMC will review safety and efﬁcacy
data during Part 1 and Part 2 of the study at predeﬁned
milestones. The DMC consist of three members with
experience in independent clinical review boards: two
clinical experts and one biostatistical expert. The DMC
is supported by two clinical pharmacology advisors.
Withdrawal
Patients have the right to withdraw from the study at any
time and for any reason. Investigators should attempt to
determine the cause of withdrawal and, if agreed by the
patient, let the patient return for the day 90 visit. The
extent of a patient’s withdrawal from the study (ie, with-
drawal from further study treatment, withdrawal from
active participation in the study, withdrawal from any
further contact) should be documented. Treatment with
study drug will be stopped when continued treatment
with study drug is not in the best interest of the patient,
if the patient withdraws consent, when investigator or
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sponsor decides to discontinue the patient’s participa-
tion in the study or when AM-Pharma terminated the
study. Additionally, treatment with study drug may be
stopped in case of protocol non-compliance or devia-
tions. In case study drug is discontinued early, the
patient will continue follow-up in the study as per proto-
col to allow for ITT analysis.
Study period
Preparations of the study are completed. The study
started enrolling patients in December 2014. Part 1 is
completed and the most efﬁcacious dose of recAP has
been selected during the interim analysis in April 2016.
The estimated study enrolment completion date of Part
2 is February 2017. Of note, this manuscript was com-
pleted prior to the interim analysis.
Ethics and dissemination
Ethics
Before study onset, the protocol, amendments, informed
consent and any other written information regarding
this study to be provided to the patient or the patient’s
legal guardian were approved by the relevant institu-
tional review boards (IRBs)/independent ethics commit-
tees (IECs). Amendments will be communicated to all
relevant parties via mail, investigator meetings and site
trainings. The study is being performed in accordance
with the ethical principles that have their origin in the
Declaration of Helsinki, ICH E6(R1), Code of Federal
Regulations and all other applicable regulations. Fully
informed consent will be obtained before any study-
speciﬁc procedures are performed. Country-speciﬁc reg-
ulations regarding the collection of personal data will be
followed at each site.
Potential conflicts of interest
During this trial, AM-Pharma, the manufacturer of
recAP, has no involvement in the randomisation, interim
analyses and dose selection, and analyses and interpret-
ation of data. AM-Pharma is involved in drafting of the
manuscript.
Confidentiality
All laboratory specimens, evaluation forms, reports and
other records will be identiﬁed in a manner designed to
maintain patient conﬁdentiality. All records will be kept
in a secure storage area with limited access. Clinical
information will not be released without the written
permission of the patient (or the patient’s legal
guardian), except as necessary for monitoring and audit-
ing by the sponsor, its designee, the Food and Drug
Administration, the European Medicines Agency, other
regulatory national authorities or the IRB/IEC. The
investigator and all employees and coworkers involved
with this study may not disclose or use for any purpose
other than performance of the study any data, record or
other unpublished, conﬁdential information disclosed
to those individuals for the purpose of the study. Prior
written agreement from the sponsor or its designee
must be obtained for the disclosure of any said conﬁden-
tial information to other parties.
Monitoring of the study
The clinical monitor, as a representative of the sponsor,
has the obligation to follow the study closely. In doing
so, the monitor will visit the investigator and study site at
periodic intervals, in addition to maintaining necessary
phone and letter contact. The monitor will maintain
current personal knowledge of the study through obser-
vation, review of study records and source documenta-
tion, and discussion of the conduct of the study with the
investigator and personnel.
Dissemination policy
After completion of the study, the data will be reported
at scientiﬁc meetings and published in a peer-reviewed
scientiﬁc journal, regardless of the outcome. Authorship
will be based on the criteria of the International com-
mittee of medical journal editors (ICMJE). There is no
intention to use a professional writer.
DISCUSSION
RecAP is one of the limited pharmaceutical treatment
options for SA-AKI currently being tested in a clinical
trial setting. Despite several attempts, many promising
new treatment strategies for AKI have failed when tested
in patients.25–27 Potential explanations include the het-
erogeneity of the study population and the complex
pathogenesis of this disease.5 Of interest, bovine-derived
intestinal AP has shown to improve renal function when
administered to critically ill patients with SA-AKI.11 12 To
further improve the renal-protective potential of AP in
the treatment of SA-AKI, recAP was developed by
replacing the crown domain of a human intestinal AP
with the crown domain of human placental AP.13 This
results in a more enzymatically stable, yet catalytically
active enzyme, as conﬁrmed by the phase I trial in
healthy volunteers.15 To investigate the efﬁcacy of recAP
in the treatment of critically ill patients with SA-AKI, we
are conducting a large multicentre phase II clinical trial.
It is thought that recAP exerts a dual mechanism of
action, targeting this multifactorial pathogenic response.
First, recAP dephosphorylates and thereby detoxiﬁes
LPS,6 7 a part of Gram-negative bacteria involved in the
development of sepsis, which can elicit an inﬂammatory
response systemically and locally within the kidney on
binding to toll-like receptor 4.28 29 Second, recAP
dephosphorylates extracellular ATP into the cytoprotec-
tive and anti-inﬂammatory signalling molecule adeno-
sine.14 Since recAP mimics the activity of an endogenous
enzyme and considering the dual mechanism of action,
recAP might be superior to other agents tested in the
past as already suggested by the previous clinical trials
performed with biAP.11 12
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In this study, sepsis is deﬁned based on a proven or
strongly suspected bacterial infection, and the presence
of at least two of the four SIRS criteria (box 1).
However, the validity of SIRS criteria to deﬁne sepsis
and the previously recognised key role of immune-
modulating mechanisms in sepsis pathogenesis are cur-
rently under debate. As such, new deﬁnitions of sepsis
and septic shock have been recently proposed, which
states that sepsis is a life-threatening organ dysfunction
caused by a dysregulated host response, and deﬁnes
sepsis as a suspected or documented infection and the
presence of organ dysfunction, deﬁned as an acute
increase of ≥2 SOFA points for one organ system.30 As
our study was designed preceding publication of these
new criteria, implementation of these criteria was not
feasible. However, we expect that we overcome the draw-
backs of the original criteria, as this study only includes
patients with sepsis combined with a failing organ
system, namely the kidney.
As there are no guidelines for the development of
drugs for SA-AKI, the study was designed by a group of
leading global experts in AKI and sepsis, with input from
the US Food and Drug Administration and the European
Medicines Agency and several local European country
authorities. The resulting design was a dose-ﬁnding adap-
tive trial. The heterogeneity of the study population,
strict inclusion criteria and narrow time-windows may
limit generalisation to the entire population of critically
ill patients with SA-AKI. On the other hand, the occur-
rence of non-responders, or speciﬁc patient groups bene-
ﬁtting the most of recAP treatment will be investigated,
which may also provide information about the potential
of recAP treatment for other nephropathies as well.
Results of this randomised controlled phase II study
will be of importance for critically ill patients with
SA-AKI, as they will allow us to draw conclusions on the
efﬁcacy of recAP in the improvement of renal function
and related clinical parameters.
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